| 摘要 |
Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Sma d signaling in a method of down-regulation of receptor signaling and downstr eam decreased production of connective tissue growth factor in ocular disord ers involving CTGF accumulation. Ocular disorders involving inappropriate CT GF accumulation include ocular hypertension, glaucoma, glaucomatous retinopa thy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and ocular wound healin g, for example. Such disorders are treated by administering antagonists of t he present invention.
|
